يعرض 1 - 20 نتائج من 96 نتيجة بحث عن '"Siskind, Carly E."', وقت الاستعلام: 0.73s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal

    جغرافية الموضوع: England

    وصف الملف: Print; application/pdf

    Relation: Brain : a journal of neurology; (2024). Brain, 147(6), 2085-2097.; https://hdl.handle.net/2292/69926; 38735647 (pubmed); 7668204

  7. 7
    Academic Journal
  8. 8
  9. 9
    Academic Journal

    مصطلحات موضوعية: Psychiatry, Health Sciences

    وصف الملف: application/pdf

    Relation: Fridman, Vera; Sillau, Stefan; Bockhorst, Jacob; Smith, Kaitlin; Moroni, Isabella; Pagliano, Emanuela; Pisciotta, Chiara; Piscosquito, Guiseppe; Laurá, Matilde; Muntoni, Francesco; Bacon, Chelsea; Feely, Shawna; Grider, Tiffany; Gutmann, Laurie; Shy, Rosemary; Wilcox, Janel; Herrmann, David N.; Li, Jun; Ramchandren, Sindhu; Sumner, Charlotte J.; Lloyd, Thomas E.; Day, John; Siskind, Carly E.; Yum, Sabrina W.; Sadjadi, Reza; Finkel, Richard S.; Scherer, Steven S.; Pareyson, Davide; Reilly, Mary M.; Shy, Michael E. (2023). "Disease Progression in Charcot- Marie- Tooth Disease Related to MPZ Mutations: A Longitudinal Study." Annals of Neurology 93(3): 563-576.; https://hdl.handle.net/2027.42/175935; Annals of Neurology; Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot-Marie-tooth disease type 2A: a large international multicentre study. Brain 2020; 143: 3589 – 3602.; Saporta AS, Sottile SL, Miller LJ. et al. Charcot-Marie-tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69: 22 – 33.; Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012; 83: 706 – 710.; Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996; 4: 25 – 33.; Callegari I, Gemelli C, Geroldi A, et al. Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype. J Neurol 2019; 266: 2629 – 2645.; Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127: 371 – 384.; Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-tooth disease type 1A. Brain 2000; 123 (pt 7 ): 1516 – 1527.; Thomas PK, Marques W Jr, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997; 120 (pt 3 ): 465 – 478.; Sanmaneechai O, Feely S, Scherer SS, et al. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain 2015; 138: 3180 – 3192.; Bird TD, Kraft GH, Lipe HP, et al. Clinical and pathological phenotype of the original family with Charcot-Marie-tooth type 1B: a 20-year study. Ann Neurol 1997; 41: 463 – 469.; Brennan KM, Bai Y, Shy ME. Demyelinating CMT—what’s known, what’s new and what’s in store. Neurosci Lett 2015; 596: 14 – 26.; Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993; 5: 31 – 34.; Volpi VG, Touvier T, D’Antonio M. Endoplasmic reticulum protein quality control failure in myelin disorders. Front Mol Neurosci 2016; 9: 162.; Grandis M, Vigo T, Passalacqua M, et al. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet 2008; 17: 1877 – 1889.; Xu W, Shy M, Kamholz J, et al. Mutations in the cytoplasmic domain of P0 reveal a role for PKC-mediated phosphorylation in adhesion and myelination. J Cell Biol 2001; 155: 439 – 446.; Wrabetz L, D’Antonio M, Pennuto M, et al. Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci 2006; 26: 2358 – 2368.; Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology 2020; 94: e884 – e896.; Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005; 64: 1209 – 1214.; Sadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot-Marie-tooth neuropathy score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst 2014; 19: 192 – 196.; Piscosquito G, Reilly MM, Schenone A, et al. Responsiveness of clinical outcome measures in Charcot-Marie-tooth disease. Eur J Neurol 2015; 22: 1556 – 1563.; Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103: 259 – 280.; Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405 – 424.; Bai Y, Ianokova E, Pu Q, et al. Effect of an R69C mutation in the myelin protein zero gene on myelination and ion channel subtypes. Arch Neurol 2006; 63: 1787 – 1794.; Dacci P, Taroni F, Bella ED, et al. Myelin protein zero Arg36Gly mutation with very late onset and rapidly progressive painful neuropathy. J Peripher Nerv Syst 2012; 17: 422 – 425.; Liu L, Li X, Zi X, et al. Two novel MPZ mutations in Chinese CMT patients. J Peripher Nerv Syst 2013; 18: 256 – 260.; De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-tooth phenotype. Brain 1999; 122 (2): 281 – 290.; Li J, Bai Y, Ianakova E, et al. Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. J Comp Neurol 2006; 498: 252 – 265.; Mandarakas MR, Menezes MP, Rose KJ, et al. Development and validation of the Charcot-Marie-tooth disease infant scale. Brain 2018; 141: 3319 – 3330.; Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012; 71: 642 – 652.; Laura M, Milani M, Morbin M, et al. Rapid progression of late onset axonal Charcot-Marie-Tooth disease associated with a novel MPZ mutation in the extracellular domain. J Neurol Neurosurg Psychiatry 2007; 78: 1263 – 1266.; Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. Arch Neurol 2010; 67: 1498 – 1505.; Fratta P, Ornaghi F, Dati G, et al. A nonsense mutation in myelin protein zero causes congenital hypomyelination neuropathy through altered P0 membrane targeting and gain of abnormal function. Hum Mol Genet 2019; 28: 124 – 132.; Eichinger K, Burns J, Cornett K, et al. The Charcot-Marie-Tooth functional outcome measure (CMT-FOM). Neurology 2018; 91: e1381 – e1384.; Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 2006; 77: 973 – 976.; Morrow JM, Evans MRB, Grider T, et al. Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A. Neurology 2018; 91: e1125 – e1129.; Morrow JM, Sinclair CD, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016; 15: 65 – 77.; Ramchandren S, Wu TT, Finkel RS, et al. Development and validation of the pediatric Charcot-Marie-Tooth disease quality of life outcome measure. Ann Neurol 2021; 89: 369 – 379.

  10. 10
    Academic Journal

    المساهمون: National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences

    المصدر: Annals of Clinical and Translational Neurology ; volume 5, issue 2, page 222-225 ; ISSN 2328-9503 2328-9503

  11. 11
    Academic Journal

    المساهمون: Institute of Medical Biology Singapore Singapore, Institute of Molecular and Cell Biology Singapore, Singapore (IMCB / A*STAR), Thérapie génique, Génomique et Epigénomique (U 1169), Molecular Imaging Research Center Fontenay-aux-Roses (MIRCEN), Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie François JACOB (JACOB), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie François JACOB (JACOB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Team 4 NeoVasc - Region Team ERI 28 INSERM (NeoVasc), Cancer and Brain Genomics (CBG), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), GeneDx Gaithersburg, MD, USA, Stanford University, The University of Jordan (JU), CHU Trousseau APHP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Sud Francilien, Barcelona Institute of Science and Technology (BIST), Universitat Pompeu Fabra Barcelona (UPF), Hôpital Jean Verdier AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), National University of Singapore (NUS), Koç University, VU University Medical Center Amsterdam

    المصدر: ISSN: 0002-9297.

    Relation: info:eu-repo/semantics/altIdentifier/pmid/28318499; PUBMED: 28318499; PUBMEDCENTRAL: PMC5384038

  12. 12
  13. 13
    Academic Journal
  14. 14
    Academic Journal

    مصطلحات موضوعية: Psychiatry, Health Sciences

    وصف الملف: application/pdf

    Relation: Ramchandren, Sindhu; Wu, Tong Tong; Finkel, Richard S.; Siskind, Carly E.; Feely, Shawna M. E.; Burns, Joshua; Reilly, Mary M.; Estilow, Timothy; Shy, Michael E. (2021). "Development and Validation of the Pediatric Charcot–Marie–Tooth Disease Quality of Life Outcome Measure." Annals of Neurology 89(2): 369-379.; https://hdl.handle.net/2027.42/166254; https://dx.doi.org/10.7302/177; Annals of Neurology; Ware JE Jr, Sherbourne CD. The MOS 36‐item Short‐Form Health Survey (SF‐36): I. Conceptual framework and item selection. Med Care 1992; 30: 473 – 483.; Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ) user’s manual. 2nd ed. Boston, MA: HealthAct, 1999.; Waters E, Salmon L, Wake M, et al. The Child Health Questionnaire in Australia: reliability, validity and population means. Aust N Z J Public Health 2000; 24: 207 – 210.; Rentz AM, Matza LS, Secnik K, et al. Psychometric validation of the Child Health Questionnaire (CHQ) in a sample of children and adolescents with attention‐deficit/hyperactivity disorder. Qual Life Res 2005; 14: 719 – 734.; Arnold A, McEntagart M, Younger DS. Psychosocial issues that face patients with Charcot‐Marie‐Tooth disease: the role of genetic counseling. J Genet Couns 2005; 14: 307 – 318.; Padua L, Aprile I, Cavallaro T, et al. Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. Neurol Sci 2006; 27: 417 – 423.; Padua L, Pareyson D, Aprile I, et al. Natural history of CMT1A including QoL: a 2‐year prospective study. Neuromuscul Disord 2008; 18: 199 – 203.; Redmond AC, Burns J, Ouvrier RA. Factors that influence health‐related quality of life in Australian adults with Charcot‐Marie‐Tooth disease. Neuromuscul Disord 2008; 18: 619 – 625.; Varni JW, Seid M, Kurtin PS. The PedsQL™ 4.0: reliability and validity of the Pediatric Quality of Life Inventory™ version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800 – 812.; Varni JW, Limbers CA. The Pediatric Quality of Life Inventory: measuring pediatric health‐related quality of life from the perspective of children and their parents. Pediatr Clin North Am 2009; 56: 843 – 863.; Vogels T, Verrips GH, Verloove‐Vanhorick SP, et al. Measuring health‐related quality of life in children: the development of the TACQOL parent form. Qual Life Res 1998; 7: 457 – 465.; McHorney CA, Ware JE Jr, Raczek AE. The MOS 36‐item Short‐Form Health Survey (SF‐36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247 – 263.; Ware JE, Kosinski M, Keller SK. SF‐36® physical and mental health summary scales: a User’s manual. Boston, MA: The Health Institute, 1994.; Burns J, Ramchandren S, Ryan MM, et al. Determinants of reduced health‐related quality of life in pediatric inherited neuropathies. Neurology 2010; 75: 726 – 731.; Boentert M, Dziewas R, Heidbreder A, et al. Fatigue, reduced sleep quality and restless legs syndrome in Charcot‐Marie‐Tooth disease: a web‐based survey. J Neurol 2010; 257: 646 – 652.; Kaiser H. An index of factorial simplicity. Psychometrika 1974; 39: 31 – 36.; Johnson NE, Heatwole C, Creigh P, et al. The Charcot‐Marie‐Tooth Health Index: evaluation of a patient‐reported outcome. Ann Neurol 2018; 84: 225 – 233.; Eichinger K, Burns J, Cornett K, et al. The Charcot‐Marie‐Tooth functional outcome measure (CMT‐FOM). Neurology 2018; 91: e1381 – e1384.; Zhao HT, Damle S, Ikeda‐Lee K, et al. PMP22 antisense oligonucleotides reverse Charcot‐Marie‐Tooth disease type 1A features in rodent models. J Clin Invest 2018; 128: 359 – 368.; Kagiava A, Richter J, Tryfonos C, et al. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum Mol Genet 2019; 28: 3528 – 3542.; Schiza N, Georgiou E, Kagiava A, et al. Gene replacement therapy in a model of Charcot‐Marie‐Tooth 4C neuropathy. Brain 2019; 142: 1227 – 1241.; Campbell A. Subjective measures of well‐being. Am Psychol 1976; 31: 117 – 124.; Skre H. Genetic and clinical aspects of Charcot‐Marie‐Tooth disease. Clin Genet 1974; 6: 98 – 118.; Passage E, Norreel JC, Noack‐Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot‐Marie‐Tooth disease. Nat Med 2004; 10: 396 – 401.; Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler‐J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007; 81: 438 – 453.; Meyer zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007; 61: 61 – 72.; Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot‐Marie‐Tooth disease type 1A in children: a randomised, double‐blind, placebo‐controlled, safety and efficacy trial. Lancet Neurol 2009; 8: 537 – 544.; Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT TRAUK): a double‐blind randomized trial. Lancet Neurol 2011; 10: 320 – 328.; Lewis RA, McDermott MP, Herrmann DN, et al. High‐dosage ascorbic acid treatment in Charcot‐Marie‐Tooth disease type 1A: results of a randomized, double‐masked, controlled trial. JAMA Neurol 2013; 70: 981 – 987.; Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the inherited neuropathies consortium natural history study: a cross sectional analysis. J Neurol Neurosurg Psychiatry 2015; 86: 873 – 878.; Ramchandren S, Shy M, Feldman E, et al. Defining disability: development and validation of a mobility‐disability severity index (mDSI) in Charcot‐Marie‐Tooth disease. J Neurol Neurosurg Psychiatry 2015; 86: 635 – 639.; Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot‐Marie‐Tooth Disease Pediatric Scale as an outcome measure of disability. Ann Neurol 2012; 71: 642 – 652.; Sadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot‐Marie‐Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst 2014; 19: 192 – 196.; Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology 2020; 94: e884 – e896.; Ouvrier R, Geevasingha N, Ryan MM. Autosomal‐recessive and X‐linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 2007; 36: 131 – 143.; Nicholson GA, Magdelaine C, Zhu D, et al. Severe early‐onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations. Neurology 2008; 70: 1678 – 1681.; Jani‐Acsadi A, Ounpuu S, Pierz K, Acsadi G. Pediatric Charcot‐Marie‐Tooth disease. Pediatr Clin North Am 2015; 62: 767 – 786.; Estilow T, Glanzman AM, Burns J, et al. Balance impairment in pediatric Charcot‐Marie‐Tooth disease. Muscle Nerve 2019; 60: 242 – 249.; Ramchandren S, Shy ME, Finkel RS. Quality of life in children with CMT type1A. Lancet Neurol 2009; 8: 880 – 881.; Burns J, Ryan MM, Ouvrier RA. Quality of life in children with Charcot‐Marie‐Tooth disease. J Child Neurol 2010; 25: 343 – 347.; Juniper EF, Guyatt GH, Feeny DH, et al. Minimum skills required by children to complete health‐related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J 1997; 10: 2285 – 2294.; Patrick DL, Erickson P. Health status and health policy. Oxford, UK: Oxford University Press, 1993.; Ramchandren S, Leonard M, Mody R, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 2009; 14: 184 – 189.; Patrick DL, Burke LB, Powers JH, et al. Patient‐reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10: S125 – S137.; US Food and Drug Administration. Guidance for industry. Patient‐reported outcome measures: use in medical product development to support labeling claims. Docket no. 2006‐D−0362. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed May 7, 2020.; Lai JS, Nowinski C, Victorson D, et al. Quality‐of‐life measures in children with neurological conditions: pediatric Neuro‐QOL. Neurorehabil Neural Repair 2012; 26: 36 – 47.; Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot‐Marie‐Tooth disease (CMT). Neuromuscul Disord 2010; 20: 839 – 846.; Landgraf J, Maunsell E, Speechley K, et al. Canadian‐French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 1998; 7: 433 – 445.

  15. 15
    Academic Journal

    المؤلفون: Siskind, Carly E

    المصدر: Clinical Chemistry ; volume 60, issue 2, page 304-305 ; ISSN 0009-9147 1530-8561

    مصطلحات موضوعية: Biochemistry (medical), Clinical Biochemistry

  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
  20. 20
    Academic Journal